Previous close | 10.44 |
Open | 10.40 |
Bid | 10.33 x 1100 |
Ask | 10.38 x 200 |
Day's range | 10.32 - 10.50 |
52-week range | 8.06 - 13.24 |
Volume | |
Avg. volume | 7,435,488 |
Market cap | 8.349B |
Beta (5Y monthly) | 1.34 |
PE ratio (TTM) | 1.97 |
EPS (TTM) | 5.27 |
Earnings date | 26 Jun 2024 - 01 Jul 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 15.90 |
Roivant’s board of directors has approved a share repurchase program for up to $1.5 billion of the company’s common shares, including an agreed repurchase of the entire Sumitomo Pharma stake for $648 millionSumitomo Pharma repurchase reduces shares outstanding by 9%In the Phase 2 NEPTUNE study of once-daily oral brepocitinib in non-infectious uveitis (NIU), the 45 mg results represent the best Treatment Failure rates observed to date among active NIU studies measuring this registrational endpoin
Roivant Sciences Ltd (NASD:ROIV) will replace Sunrun Inc. (NASD:RUN) in the S&P MidCap 400, and Sunrun will replace PGT Innovations Inc. (NYSE:PGTI) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, April 1. MITER Brands is acquiring PGT Innovations in a transaction expected to be completed on or about March 28 pending final conditions.
Roivant Sciences ( NASDAQ:ROIV ) Third Quarter 2024 Results Key Financial Results Revenue: US$37.1m (up 118% from 3Q...